| BDX |
Report |
Adjusted EPS (Q3 FY26) |
BEAT |
pred ~$3.20 vs. cons $3.15 |
MEDIUM |
| BDX |
Report |
FXN Revenue Growth (Q3 FY26) |
BEAT |
pred ~2.9% vs. cons 2.6% |
MEDIUM |
| BDX |
Report |
Adjusted Operating Margin (Q3 FY26) |
IN-LINE |
pred ~24.6% vs. cons 24.4% |
LOW |
| BDX |
Guide |
FY2026 Adjusted EPS guidance |
BETTER |
guide ~$12.68-$12.80 (mid ~$12.74) vs. cons $12.62 (FY2026) |
MEDIUM |
| BDX |
Guide |
FY2026 Revenue growth (FXN) guidance |
UNCHANGED |
guide ~2.5%-3.0% vs. cons 2.6% (FY2026) |
MEDIUM |
| BDX |
Guide |
FY2026 Adjusted Operating Margin guidance |
UNCHANGED |
guide ~25.0% vs. cons 25.0% (FY2026, inclusive of tariffs) |
MEDIUM |
| BDX |
Return |
Day-1 residual (stock − beta × S&P 500) |
+2.0% |
— |
MEDIUM |
| BDX |
Return |
5-day cumulative residual |
-1.2% (FADE) |
Stock has already rallied ~12% in the two weeks into the print (from ~$153 to ~$170.7) on UBS/Barclays target hikes, front-running a likely beat-and-modest-raise, so most good news is priced. Last quarter's pattern (Q2 FY26, reported ~May 7) showed exactly this dynamic: a sharp +~6% day-1 pop on a clean beat-and-raise fully reversed within 5 trading days even as the S&P rose, as the market shifted focus to persistent Alaris/vaccine/China headwinds, tariff-driven margin drag, and the unresolved El Paso/ChloraPrep reserve overhang that caps the size of any raise. With FY26 guidance already raised twice and the stock trading near/above the ~$175 average sell-side target, a merely in-line-to-modest-beat quarter plus an incremental (not dramatic) guidance bump is likely to see initial enthusiasm fade as investors lock in gains from the pre-print run and re-focus on FY27 Alaris headwind widening to 200bps. |
MEDIUM |